

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC  
Form 8-K  
August 06, 2002

-----  
OMB APPROVAL  
-----

OMB Number: 3235-0060  
Expires: May 31, 2000  
Estimated average burden  
hours per response....5.00  
-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
-

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) August 5, 2002  
-----

TRIANGLE PHARMACEUTICALS, INC.  
-----

(Exact name of registrant as specified in its charter)

DELAWARE

000-21589

56-1930728  
-----

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)  
-----

4 University Place, 4611 University Drive, Durham, North Carolina 27707  
-----

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (919) 493-5980  
-----

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On August 5, 2002, Triangle Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

Item 7. Financial Statements and Exhibits.

(c) Exhibits. The following document is incorporated by reference to this Report:

99.1 Press release dated August 5, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Triangle Pharmaceuticals, Inc.

-----  
(Registrant)

August 6, 2002

/s/ Chris A. Rallis

-----  
Date

-----  
(Signature)

Name: Chris A. Rallis

Title: President & Chief Operating Officer